INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2000

Collagen hydrolysate shows potential therapeutic utility in osteoarthritis and osteoporosis, with a high level of safety.

This review examined literature on collagen hydrolysate metabolism and clinical trials in osteoarthritis and osteoporosis. Clinical studies suggest that taking 10 g of pharmaceutical-grade collagen hydrolysate (PCH) daily reduces pain in knee or hip osteoarthritis, though a multicenter randomized trial found no overall statistically significant difference in mean pain scores across all sites (showing benefit primarily at German sites and among patients with more severe baseline symptoms). In osteoporosis studies, combining calcitonin with a collagen hydrolysate-rich diet produced a greater reduction in urinary pyridinoline cross-links than calcitonin alone. Reported adverse effects were minimal, mainly involving fullness or unpleasant taste.

Study type
Literature review
Who was studied
Patients with osteoarthritis or osteoporosis in clinical studies
What was measured
Pain scores, cartilage metabolism, and markers of bone collagen breakdown

THE PAPER

Role of collagen hydrolysate in bone and joint disease.

Moskowitz RW. Semin Arthritis Rheum, 2000.

PubMed 11071580 ↗DOI 10.1053/sarh.2000.9622 ↗

Bones & musclesOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.